Elite Pharmaceuticals, Inc.

ELITE PHARMACEUTICALS INC is a specialty pharmaceutical company focused on the development and manufacture of oral, controlled-release products and generic pharmaceuticals. The company was reincorporated under the laws of the State of Nevada on January 5, 2012. Its strategy involves developing generic versions of controlled-release drug products that have high barriers to entry. ELITE PHARMACEUTICALS INC operates from manufacturing, warehouse, laboratory, and office space located at 135, 144, and 165 Ludlow Avenue in Northvale, NJ, referred to as the Northvale Facility. This facility adheres to Current Good Manufacturing Practice (cGMP) standards and is registered with the United States Drug Enforcement Agency (DEA) for research, development, and manufacturing activities. The company's strategy focuses on several key areas: manufacturing a line of generic pharmaceutical products with approved Abbreviated New Drug Applications (ANDAs); developing additional generic pharmaceutical products; advancing other product candidates in its pipeline, including those co-developed with partners; commercially exploiting its products through sales under its own label, licensing and royalty collection, or manufacturing its formulations; and developing new products for sale under its own label, alongside expanding licensing agreements with other pharmaceutical companies, including co-development projects, joint ventures, and other collaborations. ELITE PHARMACEUTICALS INC evaluates opportunities for various drug products, including branded drug products requiring New Drug Applications (NDAs) under Section 505(b)(1) or 505(b)(2) of the Drug Price Competition and Patent Term Restoration Act of 1984, as well as generic drug products requiring ANDAs. The company aims to reduce risk through a diverse product portfolio.